Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Alligator Bioscience ABFRA:7AL0 Receivables Turnover is 0.00 as of Mar. 2026. The stock has 7 warning signs investors should review. Among 841 Biotechnology companies, Alligator Bioscience AB ranks worse than 86.68% on this metric.
The Receivables Turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by average Accounts Receivable. An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. Alligator Bioscience AB's Revenue for the
three
months ended in Mar. 2026 was €0.00 Mil. Alligator Bioscience AB's average Accounts Receivable for the
three
months ended in Mar. 2026 was €0.00 Mil.
Alligator Bioscience AB (FRA:7AL0) Receivables Turnover Explanation
An efficient company has a higher accounts receivable turnover ratio while an inefficient company has a lower ratio. This metric is commonly used to compare companies within the same industry to check whether they are on par with their competitors.
Alligator Bioscience AB Receivables Turnover Related Terms
Alligator Bioscience AB Receivables Turnover Historical Data
* Premium members only.
The historical data trend for Alligator Bioscience AB's Receivables Turnover can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB Receivables Turnover Chart
FRA:7AL0 vs VRTX, REGN, ALNY: Receivables Turnover Comparison
For the Biotechnology subindustry, Alligator Bioscience AB's Receivables Turnover, along with its competitors' market caps and Receivables Turnover data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Alligator Bioscience AB Receivables Turnover vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Alligator Bioscience AB's Receivables Turnover distribution charts can be found below:
* The bar in red indicates where Alligator Bioscience AB's Receivables Turnover falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Alligator Bioscience AB (FRA:7AL0) has a Receivables Turnover of 0.00 as of Mar. 2026. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alligator Bioscience AB and its competitors. According to the industry distribution chart, Alligator Bioscience AB ranks #729 out of 841 companies in the Biotechnology industry, placing it in the top 86.7%.
Is Alligator Bioscience AB's Receivables Turnover too high?
Alligator Bioscience AB's current Receivables Turnover is 0.00. Based on the distribution chart, Alligator Bioscience AB ranks #729 out of 841 companies in the Biotechnology industry, which is in the bottom quartile relative to peers.
How does Alligator Bioscience AB's Receivables Turnover compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Alligator Bioscience AB ranks #729 out of 841 companies for Receivables Turnover. This places Alligator Bioscience AB in the lower half of its industry. The industry median Receivables Turnover is 5.27. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Receivables Turnover for a Biotechnology company?
The median Receivables Turnover among Biotechnology companies is 5.27, based on 841 companies in the industry. Companies in the top quartile (top 25%) have a Receivables Turnover significantly above this median, while those in the bottom quartile fall well below. However, Receivables Turnover should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Receivables Turnover mean?
A high Receivables Turnover can signal that a stock is expensive relative to its fundamentals. The accounts receivables turnover ratio measures the number of times a company collects its average accounts receivable balance. It is calculated as Revenue divided by Average Accounts Receivable. View historical data on Alligator Bioscience AB and its competitors. For the Biotechnology industry, the median Receivables Turnover is 5.27 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Alligator Bioscience AB's current Receivables Turnover is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Alligator Bioscience AB stock overvalued right now?
Alligator Bioscience AB (FRA:7AL0) has a current Receivables Turnover of 0.00. The current Receivables Turnover is 0.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Receivables Turnover calculated?
Receivables Turnover is calculated from a company's financial statements. For Alligator Bioscience AB (FRA:7AL0), the current Receivables Turnover is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Alligator Bioscience AB is a clinical-stage biotechnology company developing tumor-directed immuno-oncology antibody drugs focused on the CD40 receptor. The company's main drug candidate, mitazalimab, is currently under development as a therapy for metastatic pancreatic cancer patients. Its development pipeline also comprises: ATOR-4066, a bispecific antibody targeting CD40, as well as CEACAM5 (carcinoembryonic antigen 5), a protein found in certain tumors; and certain externally developed programs like HLX22 and ALG.APV-527. Geographically, the company generates maximum revenue from Belgium (mainly through out-licensing), and also has its presence in Sweden and Finland.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:7AL0 has been successfully added to your 
